Prostate stromal cell telomere shortening is associated with risk of prostate cancer in the placebo arm of the Prostate Cancer Prevention Trial

Publisher： John Wiley & Sons Inc

E-ISSN： 1097-0045|75|11|1160-1166

ISSN： 0270-4137

Source： THE PROSTATE, Vol.75, Iss.11, 2015-08, pp. : 1160-1166

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Variation in genes involved in the immune response and prostate cancer risk in the placebo arm of the Prostate Cancer Prevention Trial

By  

THE PROSTATE, Vol. 75, Iss. 13, 2015-09 ,pp. : 1403-1418

John Wiley & Sons Inc

Access to resources Recommend Favorite

Current or recent smoking is associated with more variable telomere length in prostate stromal cells and prostate cancer cells

By  

THE PROSTATE, Vol. 78, Iss. 3, 2018-02 ,pp. : 233-238

John Wiley & Sons Inc

Access to resources Recommend Favorite

The Use of the Finasteride-Adjusted Prostate Cancer Prevention Trial Prostate Cancer Risk Calculator in a Mexican Referral Population: A Validation Study

By  

Urologia Internationalis, Vol. 89, Iss. 1, 2012-05 ,pp. : 9-16

Karger

Access to resources Recommend Favorite

Multiparametric magnetic resonance imaging outperforms the Prostate Cancer Prevention Trial risk calculator in predicting clinically significant prostate cancer

By  

CANCER, Vol. 120, Iss. 18, 2014-09 ,pp. : 2876-2882

John Wiley & Sons Inc

Access to resources Recommend Favorite

The Prostate Cancer Prevention Trial risk calculator and the relationship between prostate‐specific antigen and biopsy outcome

By  

CANCER, Vol. 119, Iss. 16, 2013-08 ,pp. : 3007-3011

John Wiley & Sons Inc

Access to resources Recommend Favorite